Chen-Ting (Kelly) Lee, PhD, is currently the Associate Director of Oncology Safety Science at AstraZeneca, having previously acted as the Associate Director and In Vivo Pharmacology Lead at Senti Biosciences. With nearly 18 years of preclinical modeling experience, they possess strategic and technical expertise in preclinical drug development and pharmacology, particularly within the realms of immuno-oncology, tumor immunology, and nanotechnology. Chen-Ting completed a PhD in Immunology at Roswell Park Cancer Institute, where their research focused on macrophage function and chronic inflammatory diseases. Their career spans positions at Duke University Medical Center, AbGenomics Corp, and Roswell Park Cancer Institute, fostering collaboration across multidisciplinary teams and contributing to numerous preclinical studies and therapeutic developments.
This person is not in the org chart
This person is not in any teams
This person is not in any offices